ALS Drug Receives Patent In Israel, Europe, Japan

By Ariel Grossman, NoCamels September 20, 2023 < 1 minute

The late Stephen Hawking, a physicist, cosmologist and author who suffered from a rare, early-onset form of ALS (Courtesy NASA)

An Israeli company that develops treatments for severe neurodegenerative diseases has patented a new therapeutic drug for Amyotrophic Lateral Sclerosis (ALS) in Europe, Japan and Israel.

ALS is a progressive disease that causes the degeneration of motor neurons in the brain and spinal cord, eventually resulting in the inability to speak, eat, move and breathe.

NeuroSense Therapeutics’ PrimeC therapy uses a fixed-dose combination of ciprofloxacin and celecoxib, two drugs already approved by the US Food and Drug Administration (FDA) to treat bacterial infections and relieve symptoms of arthritis, respectively. The company has already received similar patents in the US, Canada and Australia.

“We are pleased to receive this most recent patent grant in Europe, Japan, and Israel, which adds to our growing IP estate as we expect the clinical read-out from our PARADIGM Phase 2b study towards year’s end,” said Alon Ben-Noon, NeuroSense’s CEO.

“ALS remains a pressing unmet need, and our unwavering commitment to advancing our program, supported by robust intellectual property, underscores our dedication to delivering an effective therapy for individuals battling ALS.”

NeuroSense is currently recruiting patients with ALS for a clinical trial that will evaluate the safety and efficacy of PrimeC.

In the trial, 69 participants will be administered the drug or a placebo twice daily for six months. All patients will then receive PrimeC for a year.